0.5621 - 2.41
Join Discuss about IMV with like-minded investors
IMV trying to push above vwap
106 Replies 14 👍 10 🔥
"This is a slight detour from your guys’ pts but this is why the “invest intl for growth” is a failed narrative imv Investing in FM, EM, and most DM-exUS is a bet on banks and resource extraction (aka bad bets mostly) The real growth in the “once they emerge from FM->EM” is almost entirely in consumer disc and tech - and those are mostly captured by US firms. So want to bet on the growth of south korea etc you buy nike and visa amzn and thats obv not reflected in those geo indices"
89 Replies 7 👍 11 🔥
Thanks for calling IMV. halted down. short from 6.7
71 Replies 15 👍 7 🔥
IMV halted on the way down
139 Replies 13 👍 11 🔥
Next Dividend Date
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer immunotherapies based on the Company's proprietary delivery platform (DPX). This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects. IMV's lead candidate, Maveropepimut-S, is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing Maveropepimut-S in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19. Visit www.imv-inc.com and connect with us on Twitter and LinkedIn.